{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:50:01Z","timestamp":1789390201197,"version":"build-2803163510"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:p>We describe a case of invasive meningococcal disease due to a vaccine-preventable and penicillin-resistant strain in a fully immunized young adult on long-term complement inhibitor therapy and daily penicillin chemoprophylaxis. Eculizumab is a humanized monoclonal antibody that binds human complement C5 protein and inhibits the terminal complement pathway. It is currently recommended for the treatment of complement-mediated thrombotic microangiopathies. An unwanted complication of inhibiting complement, however, is an increased risk of invasive meningococcal disease. Here, we report the first case of meningococcal group B vaccine failure in a young adult receiving eculizumab for atypical hemolytic uremic syndrome. She developed invasive meningococcal disease due to a vaccine-preventable and penicillin-resistant meningococcal group B strain 4 months after receiving 2 doses of meningococcal group B vaccine while on oral penicillin prophylaxis against meningococcal infection.<\/jats:p>","DOI":"10.1542\/peds.2016-2452","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T09:10:09Z","timestamp":1502442609000},"source":"Crossref","is-referenced-by-count":40,"title":["Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab"],"prefix":"10.1542","volume":"140","author":[{"given":"Sydel R.","family":"Parikh","sequence":"first","affiliation":[{"name":"Immunisation, Hepatitis, and Blood Safety Department, Public Health England, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lucidarme","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Bingham","sequence":"additional","affiliation":[{"name":"Exeter Kidney Unit, Royal Devon and Exeter Hospital, Devon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Warwicker","sequence":"additional","affiliation":[{"name":"Lister Renal Unit, Lister Hospital, Hertfordshire, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Goodship","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, Newcastle University, Newcastle, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez N.","family":"Ladhani","sequence":"additional","affiliation":[{"name":"Immunisation, Hepatitis, and Blood Safety Department, Public Health England, London, United Kingdom;"},{"name":"St George\u2019s University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"issue":"12","key":"2021120916123329500_B1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"2021120916123329500_B2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2021120916123329500_B3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2015.08.009","article-title":"Applying complement therapeutics to rare diseases.","volume":"161","author":"Reis","year":"2015","journal-title":"Clin Immunol"},{"issue":"2","key":"2021120916123329500_B4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOP.0b013e32835df4a3","article-title":"Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.","volume":"25","author":"Nester","year":"2013","journal-title":"Curr Opin Pediatr"},{"issue":"3-4","key":"2021120916123329500_B5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000368592","article-title":"Eculizumab in the treatment of membranoproliferative glomerulonephritis.","volume":"128","author":"Bomback","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2021120916123329500_B6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","article-title":"Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?","volume":"2012","author":"Nester","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021120916123329500_B7","unstructured":"US Food and Drug Administration. Solaris (Eculizumab) postmarket drug safety information for patients and providers. Available at: https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformation%20forPatientsandProviders\/UCM217725.pdf. Accessed June 16, 2017"},{"issue":"2","key":"2021120916123329500_B8","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"2021120916123329500_B9","unstructured":"Public Health England. Meningococcal: the green book, chapter 22. Available at: https:\/\/www.gov.uk\/government\/publications\/meningococcal-the-green-book-chapter-22. Accessed June 16, 2017"},{"issue":"4","key":"2021120916123329500_B10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome.","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"issue":"3","key":"2021120916123329500_B11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies.","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2021120916123329500_B12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02918259","article-title":"Complement deficiency states and meningococcal disease.","volume":"12","author":"Figueroa","year":"1993","journal-title":"Immunol Res"},{"key":"2021120916123329500_B13","volume-title":"Effect of the Eculizumab (Solaris), on the Meningococcal Serogroup B Serum Bactericidal Antibody Activity and Opsonophagocytic Activity.","author":"Findlow","year":"2015"},{"issue":"18","key":"2021120916123329500_B14","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s40265-013-0147-7","article-title":"Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"issue":"6","key":"2021120916123329500_B15","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2014-3503","article-title":"Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.","volume":"135","author":"Cullinan","year":"2015","journal-title":"Pediatrics"},{"issue":"3","key":"2021120916123329500_B16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination.","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"2021120916123329500_B17","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1111\/j.1399-3046.2011.01585.x","article-title":"Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.","volume":"16","author":"Zlamy","year":"2012","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2021120916123329500_B18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"2021120916123329500_B19","unstructured":"Group aRD. Atypical haemolytic uraemic syndrome (aHUS) \u2013 clinician information. Available at: http:\/\/rarerenal.org\/clinician-information\/haemolytic-uraemic-syndrome-atypical-ahus-clinician-information\/. Accessed January 18, 2016"},{"issue":"1","key":"2021120916123329500_B20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children.","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2021120916123329500_B21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome\u2014the first year\u2019s experience.","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2452\/1104312\/peds_20162452.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2452\/1104312\/peds_20162452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T04:21:38Z","timestamp":1639110098000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/140\/3\/e20162452\/38304\/Meningococcal-B-Vaccine-Failure-With-a-Penicillin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9,1]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-2452","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,1]]},"article-number":"e20162452"}}